ORIGINAL RESEARCH article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
This article is part of the Research TopicCell Models and Preclinical Validation of Immune-Mediating Biological TherapiesView all 9 articles
Evaluation of a Reference Antibody Panel for Prediction of Cytokine Release in Humanised Mouse Models in vivo
Provisionally accepted
- Other
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
A diverse range of innovative biological therapies is being developed to treat various human diseases. The safety assessment of these biologics is a critical factor determining clinical success. Enhanced humanised mouse models have the potential to revolutionise immunotoxicological profiling by refining procedures for effective in vivo safety assessments. We evaluated a novel reference panel of recombinant monoclonal antibodies (mAbs) with varying cytokine release (CR) potential to assess the sensitivity of specific humanised mouse models. The in vitro CR capacity of the reference panel was previously evaluated in an international collaborative study. We present here the in vivo assessment of the reference Ab panel, 19/156, using NOD-scid-gamma (NSG) mice reconstituted with either umbilical cord-derived hematopoietic human (CD34+) stem cells (HSC) or human peripheral blood mononuclear cells (PBMC) from healthy donors. Our manuscript discusses a comparative evaluation of both forms of engraftment and the CR patterns in response to the reference panel. The in vivo CR pattern is discussed in relation to in vitro assays using the same PBMC donor cohort. The manuscript discusses the utility of these humanised mice as a model for translational use in hazard identification and preclinical safety assessment. The results highlight the importance of incorporating standardised reference materials to evaluate, qualify, and harmonise preclinical models for translational use. This approach aims to enhance the predictability and reliability of both in vitro and in vivo safety assessments, thereby supporting the development of safe and effective biological therapies.
Keywords: Cytokine release, Hazard identification, Human peripheral blood mononuclear cells (PBMC), humanised mouse models, NOD-scid-gamma (NSG) mice, Preclinical safety assessment, recombinant monoclonal antibodies, reference antibody panel
Received: 30 Oct 2025; Accepted: 02 Feb 2026.
Copyright: © 2026 Rajagopal, Ieong, Mate and Vessillier. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Deepa Rajagopal
Sandrine Vessillier
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.